AD Scientific Index (Alper-Doger Scientific Index) offers the broadest spectrum of branches, providing analysis in 13 main fields and 197 sub-branches at global, national, and regional levels. These analyses can be based on indicators such as the H-index, i10-index, and citation count, as well as their values from the last 6 years. As of Nov 25, 2024, rankings are according to the Total H Index. BETA VERSION: The subject field rankings for the world, regions, countries, and universities are currently in beta. This is due to the exclusion of (873.863) scientists categorized under 'others,' whose profiles cannot yet be determined, edited, or classified. As these fields are updated, the rankings will adjust accordingly. Please keep this in mind. See Also: [University Subject Rankings]
* Total H IndexRankings
Ranking Based On Selection
:76
cancer cell biology
genetics
Metrics
H-Index
i10 Index
Citation Counts
3
3
57
* Total H IndexRankings
Ranking Based On Selection
:77
Metrics
H-Index
i10 Index
Citation Counts
3
1
139
* Total H IndexRankings
Ranking Based On Selection
:78
cancer immunology
Metrics
H-Index
i10 Index
Citation Counts
3
1
68
* Total H IndexRankings
Ranking Based On Selection
:79
nanoformulations
cancer therapies
cardiovascular therapies
atherosclerosis
transdermal delivery of anesthetics
Metrics
H-Index
i10 Index
Citation Counts
3
1
28
* Total H IndexRankings
Ranking Based On Selection
:80
Kidney fibrosis
kidney injury
Metrics
H-Index
i10 Index
Citation Counts
2
2
68
* Total H IndexRankings
Ranking Based On Selection
:81
Nanoparticles based drug delivery
Metrics
H-Index
i10 Index
Citation Counts
2
2
59
* Total H IndexRankings
Ranking Based On Selection
:82
Metrics
H-Index
i10 Index
Citation Counts
2
2
46
* Total H IndexRankings
Ranking Based On Selection
:83
UCNP
Metrics
H-Index
i10 Index
Citation Counts
1
1
22
* Total H IndexRankings
Ranking Based On Selection
:84
Metrics
H-Index
i10 Index
Citation Counts
1
1
18
* Total H IndexRankings
Ranking Based On Selection
:85
Patient Safety、Rare disease、Health Policy
Metrics
H-Index
i10 Index
Citation Counts
1
0
3
Hamza Fares
China Pharmaceutical University
Nanjing, China
Metrics
H-Index
i10-Index
Citation Counts
3
3
57
cancer cell biology
genetics
Yexiang Chen
China Pharmaceutical University
Nanjing, China
Metrics
H-Index
i10-Index
Citation Counts
3
1
139
Zemeng Ma
China Pharmaceutical University
Nanjing, China
Metrics
H-Index
i10-Index
Citation Counts
3
1
68
Amari Mohammed Khamis
China Pharmaceutical University
Nanjing, China
Metrics
H-Index
i10-Index
Citation Counts
3
1
28
nanoformulations
cancer therapies
cardiovascular therapies
atherosclerosis
transdermal delivery of anesthetics
Lifei Gu
China Pharmaceutical University
Nanjing, China
Metrics
H-Index
i10-Index
Citation Counts
2
2
68
Kidney fibrosis
kidney injury
Bholakant Raut
China Pharmaceutical University
Nanjing, China
Metrics
H-Index
i10-Index
Citation Counts
2
2
59
Nanoparticles based drug delivery
Canyong Guo
China Pharmaceutical University
Nanjing, China
Metrics
H-Index
i10-Index
Citation Counts
2
2
46
Yang Yueyan
China Pharmaceutical University
Nanjing, China
Metrics
H-Index
i10-Index
Citation Counts
1
1
22
Aklima Afroze
China Pharmaceutical University
Nanjing, China
Metrics
H-Index
i10-Index
Citation Counts
1
1
18
Meng Han
China Pharmaceutical University
Nanjing, China
Metrics
H-Index
i10-Index
Citation Counts
1
0
3
Patient Safety、Rare disease、Health Policy